These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3067 related articles for article (PubMed ID: 31686097)

  • 1. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.
    Alexopoulos P; Roesler J; Thierjung N; Werle L; Buck D; Yakushev I; Gleixner L; Kagerbauer S; Ortner M; Grimmer T; Kübler H; Martin J; Laskaris N; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):587-97. PubMed ID: 26253588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
    Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
    Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
    J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study.
    Pais M; Loureiro J; do Vale V; Radanovic M; Talib L; Stella F; Forlenza O
    J Alzheimers Dis; 2021; 81(3):949-962. PubMed ID: 33843685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
    Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
    J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
    Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
    Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 154.